| 2026-03-20 |
详情>>
内部人交易：
Okupe Oluyemi共交易2笔
|
| 2026-02-23 |
详情>>
股本变动：
变动后总股本22793.88万股
|
| 2026-02-23 |
详情>>
业绩披露：
2025年年报每股收益0.57美元,归母净利润1.28亿美元,同比去年增长1.85%
|
| 2026-02-23 |
财报披露：
美东时间 2026-02-23 盘后发布财报
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.48美元,归母净利润1.08亿美元,同比去年增长7.75%
|
| 2025-08-04 |
详情>>
业绩披露：
2025年中报每股收益0.41美元,归母净利润9199.00万美元,同比去年增长276.62%
|
| 2025-05-05 |
详情>>
业绩披露：
2025年一季报每股收益0.22美元,归母净利润4948.50万美元,同比去年增长344.69%
|
| 2025-04-25 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the ten director nominees to serve until the 2026 annual meeting of stockholders;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any continuation or adjournment thereof.
|
| 2025-02-24 |
详情>>
业绩披露：
2022年年报每股收益-0.32美元,归母净利润-6567.8万美元,同比去年增长38.99%
|
| 2025-02-24 |
详情>>
业绩披露：
2024年年报每股收益0.58美元,归母净利润1.26亿美元,同比去年增长635.28%
|
| 2024-11-04 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.12美元,归母净利润-2479.1万美元,同比去年增长54.74%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.47美元,归母净利润1.00亿美元,同比去年增长503.42%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益0.11美元,归母净利润2442.50万美元,同比去年增长241.81%
|
| 2024-05-06 |
详情>>
业绩披露：
2024年一季报每股收益0.05美元,归母净利润1112.80万美元,同比去年增长210.54%
|
| 2024-04-26 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees to serve until the 2025 annual meeting of stockholders;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any continuation or adjournment thereof.
|
| 2024-02-26 |
详情>>
业绩披露：
2023年年报每股收益-0.11美元,归母净利润-2354.6万美元,同比去年增长64.15%
|
| 2023-04-28 |
股东大会：
将于2023-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees to serve until the 2024 annual meeting of stockholders;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any continuation or adjournment thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.To elect the 10 director nominees to serve until the 2023 annual meeting of stockholders;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To approve, on an advisory basis, the frequency of holding future advisory votes on executive compensation;
5.To transact such other business as may properly come before the Annual Meeting or any continuation or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-17 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.To elect all nine of our existing directors to serve until the 2022 annual meeting of stockholders.
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2020-12-29 |
股东大会：
将于2021-01-19召开股东大会
会议内容 ▼▲
- 1.Pursuant to the Sponsor Agreement between OAC, Oaktree Acquisition Holdings, L.P. (the “Sponsor”) and Hims (the “Sponsor Agreement”), the Sponsor will surrender and forfeit for no consideration to OAC 25.0% of the Class B ordinary shares of OAC (the “Class B ordinary shares”) and 25.0% of the private placement warrants of OAC. A number of securities equal to such surrendered and forfeited Class B ordinary shares and private placement warrants is being issued to the equityholders of Hims (the “Hims Equityholders”) as shares of Class A common stock, par value $0.0001 per share, of New Hims (the “New Hims Class A Common Stock”) (or equivalent equity awards in respect thereof) and warrants to acquire shares of New Hims Class A Common Stock (or equivalent equity awards in respect thereof) in the Business Combination.
2.On the Closing Date, prior to the time at which the Merger (as defined below) becomes effective (the “Effective Time”), OAC will change its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication”), upon which OAC will change its name to “Hims & Hers Health, Inc.” (“New Hims”) (for further details, see “Proposal No. 2—The Domestication Proposal”).
3.At the Effective Time, OAC Merger Sub will merge with and into Hims (the “Merger”), with Hims as the surviving company in the Merger and, after giving effect to such Merger, Hims shall be a wholly-owned subsidiary of New Hims. Immediately prior to the Effective Time, each share of Hims preferred stock and Hims Class F common stock will convert into Hims Class A common stock at the applicable then-effective conversion rate (the “Hims Recapitalization”). In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time, based on an implied equity value of $1.6 billion, minus up to $75 million of cash consideration to Hims stockholders at Hims’ election, plus the aggregate strike price of all Hims options and warrants outstanding and unexercised as of immediately prior to the Effective Time, (i) each share of Hims Class A Common Stock and Hims Class V Common Stock and Hims restricted stock outstanding as of immediately prior to the Effective Time (other than dissenting shares and shares held by Hims as treasury stock (which treasury shares will be cancelled for no consideration as part of the Merger)) will be cancelled and converted into the right to receive the applicable portion of the merger consideration comprised of New Hims Class A Common Stock (or, solely with respect to the Hims Class V Common Stock, New Hims Class V Common Stock), Earn Out Shares (as defined below) and warrants to acquire shares of New Hims Class A Common Stock, each as determined in the Merger Agreement, (ii) all equity awards of Hims will be assumed by OAC and converted into comparable equity awards that are settled or exercisable for shares of New Hims Class A Common Stock, earn out restricted stock unit awards and warrant restricted stock unit awards with a value as if such Hims equity awards were exercised or settled immediately prior to the closing of the Business Combination (the “Closing”) and (iii) each warrant of Hims that is unexercised will be assumed by OAC and represent the right to receive the applicable portion of the merger consideration upon exercise of such warrant as if such warrant was exercised prior to the Closing. Each Hims Equityholder will receive its applicable portion of the 16 million restricted shares of New Hims Class A Common Stock (or equivalent equity award) described above that will vest (in part) in equal thirds if the trading price of New Hims Class A Common Stock is greater than or equal to $15, $17.50 and $20 for any 10 trading days within any 20-trading day period on or prior to the date that is five years following the Effective Time and will also vest in connection with any Company Sale (as defined in the Merger Agreement) if the applicable thresholds are met in such Company Sale but subject to the same five-year deadline (the “Earn Out Shares”).
|